Rao, M;
Valentini, D;
Dodoo, E;
Zumla, A;
Maeurer, M;
(2017)
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.
International Journal of Infectious Diseases
, 56
pp. 221-228.
10.1016/j.ijid.2017.01.028.
Preview |
Text
Zumla_1-s2.0-S1201971217300310-main (1).pdf - Published Version Download (1MB) | Preview |
Abstract
OBJECTIVES: Immune checkpoint pathways regulate optimal host immune responses against transformed cells, induce immunological memory, and limit tissue pathology. Conversely, aberrant immune checkpoint activity signifies a poor prognosis in cancer and infectious diseases. Host-directed therapy (HDT) via immune checkpoint blockade has revolutionized cancer treatment with therapeutic implications for chronic infections, thus laying the foundation for this review. METHODS: Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specific cells”; “tuberculosis”; “malaria”; “viral infections”; “human immunodeficiency virus”; “hepatitis B virus”; “hepatitis C virus”; “cytomegalovirus” and “Epstein–Barr virus”. Search results were filtered based on relevance to the topics covered in this review. RESULTS: The use of monoclonal antibodies directed against the antigen-experienced T-cell marker programmed cell death 1 (PD-1) and its ligand PD-L1 in the context of chronic infectious diseases is reviewed. The potential pitfalls and precautions, based on clinical experience from treating patients with cancer with PD-1/PD-L1 pathway inhibitors, are also described. CONCLUSIONS: Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious diseases such as tuberculosis and HIV, and must therefore be tested in randomized clinical trials.
| Type: | Article |
|---|---|
| Title: | Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ijid.2017.01.028 |
| Publisher version: | http://dx.doi.org/10.1016/j.ijid.2017.01.028 |
| Language: | English |
| Additional information: | © 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/) |
| Keywords: | Anti-PD-1; Anti-PD-L1; T-cells; Cancer; Infectious disease; Host-directed therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1551409 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
